At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
AZR-MD-001 Vehicle +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-center, Vehicle-controlled, Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZR-MD-001 as Adjunctive Therapy to Conventional Therapeutic Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)
In Brief
A Phase 2 clinical trial evaluating AZR-MD-001 Vehicle and AZR-MD-001 Active Dose for Meibomian Gland Dysfunction (MGD) and Contact Lens Discomfort (CLD). Completed, enrolled 26 participants across 1 site.
Detailed Summary
SOVS2019-070 is a single-center study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia
CollaboratorsThe University of New South Wales
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartOct 2019
Primary CompletionDec 2020
TodayJul 2026
First PostedJun 3, 2019
Enrollment StartOct 4, 2019
Primary CompletionDec 11, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.1 years ago
Interventions
AZR-MD-001 Vehicledrug
AZR-MD-001 is an ophthalmic ointment
AZR-MD-001 Active Dosedrug
AZR-MD-001 is an ophthalmic ointment